Tokai’s prostate cancer drug implodes in PhIII debacle
Just short of two years after Boston-based Tokai Pharmaceuticals $TKAI raised $97 million in an IPO, the small-cap biotech says its lead drug has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
